NCT04641078 2024-02-28
DART
University Hospital, Ghent
Phase 2 Unknown
Clinical Trials
3 trialsNCT05900973 2023-08-07
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
D'Or Institute for Research and Education
Phase 2 Unknown
NCT05249712 2023-01-03
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown